This is a wild guess, but the upcoming FDA advisory panel for BI’s flibanserin could have caused someone at the FDA to take another look at the size of the LibiGel safety trials.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”